Only the biggest developers can play the biosimilar game

Over the next five years, the market for biosimilars will swell to $10 billion, but only a handful of players with deep pockets and world-class R&D facilities will be able to play. And that means that most small- and medium-size drug developers will never have a chance of leaping into the new market for follow-on biologics. "You are not going to see small shops being able to enter this market... There are only five to six players that are credibly going to play a role," Michael Sjoestroem,...